Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Sponsor
Alexandria University
Study ID
NCT05200793
Phase
PHASE4
Status
Unknown

Conditions

  • Polycystic Ovary Syndrome (PCOS)

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 40 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 25 mg — DRUG
    This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
  • Linagliptin 10 mg — DRUG
    This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
  • Metformin 1500 mg — DRUG
    This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)

Study Details

The study aims to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS).

Key Dates

Start date
Dec 7, 2021
Status verified
Jan 2022
Primary completion
Jul 1, 2022
Completion
Sep 1, 2022

Study Design

Enrollment
75 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Metformin arm (control group)
    Patients will receive Metformin (1500 mg orally/day) for 12 weeks .
  • Active Comparator: Empagliflozin arm
    Patients will receive Empagliflozin (25 mg orally/day) for 12 weeks.
  • Active Comparator: Linagliptin arm
    Patients will receive Linagliptin (10 mg orally/day) for 12 weeks

Primary Outcome Measure

Fertility parameters [ Time Frame: 3-6 months ]

Central Contacts

Related Studies